CCS
EGRX

Crosspoint Capital Strategies’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Crosspoint Capital Strategies’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-126
Closed -$10K – 906
2015
Q2 		$10K Buy
+126
New +$8.21K ﹤0.01% 532

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
GE
General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

Crosspoint Capital Strategies's EGRX Position: Q3 2015 in Review

Crosspoint Capital Strategies sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2015, closing a stake of 126 shares — an estimated $10K sold.

Crosspoint Capital Strategies first reported a position in EGRX in Q2 2015 and held it in 1 quarter. The position peaked at $10K in Q2 2015. 119 funds tracked by Wall St. Rank hold EGRX as of Q3 2015.

  • Crosspoint Capital Strategies reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 126 Eagle Pharmaceuticals, Inc. shares in Q3 2015, an estimated $10K.
  • Crosspoint Capital Strategies first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • Crosspoint Capital Strategies's Eagle Pharmaceuticals, Inc. position peaked at $10K in Q2 2015.
  • 119 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2015.

Based on Crosspoint Capital Strategies's 13F filing for Q3 2015, filed 25 Nov 2015.